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ABSTRACT
Purpose Since 1997, strong incentives have been
introduced worldwide to improve access to safe and
effective medicines addressing the therapeutic needs of
children. ACE inhibitors, the most prescribed
antihypertensive drugs in the paediatric population, are
one of the prototype drugs targeted by the legislation
initiatives. Our purpose in assembling this review is to
evaluate and describe the current evidence for the
efﬁcacy and safety proﬁle of ACE inhibitors in the
paediatric population.
Methods The authors made a descriptive review of the
literature from 1980 to 2015 using the following search
terms: hypertension, child, paediatric, ACE (inhibitors),
renin–angiotensin aldosterone system, captopril,
lisinopril, enalapril, ramipril and fosinopril.
Results A total of 16 studies evaluating efﬁcacy and
safety of ACE inhibitors were included in this review. The
included studies demonstrate that ACE inhibitors have
the potency to decrease the systolic and/or diastolic
blood pressure with an overall favourable safety proﬁle in
a short-term period. More importantly, the incentives
resulted in an improvement of the overall availability of
paediatric labelling, dosing and safety information for
ACE inhibitors. However, they failed to fulﬁl several of
paediatric needs: absence of long-term safety data on
growth and maturation, absence of commercially
available child-friendly formulations and incomplete
evaluation of the entire paediatric hypertension
population.
Conclusion Additional efforts are needed to close the
gap between the availability of drugs that are labelled
and indicated for paediatric use and the actual drug
usage in children, especially in young children, neonates
and children with severe hypertension, renal
transplantation or severe renal impairment.
INTRODUCTION
Hypertension is increasingly recognised as an im-
portant disease in childhood. Hypertension is diag-
nosed in childhood, according to the National
High Blood Pressure Group 2004, when an average
systolic blood pressure (SBP) and/or diastolic blood
pressure (DBP) is found to be on the 95th percent-
ile or above for age, gender and height on at least
three separate occasions.1 It is widely accepted that
early identiﬁcation and treatment of hypertensive
children may possibly prevent the development of
established hypertension and its complications in
adulthood.2 3
ACE inhibitors have the power to restore the
balance between two endogenous systems that are
predominantly affected in the pathogenesis of
hypertension in childhood: the renin–angiotensin
system (RAS) and the kallikrein–kinin system.4
Blocking of ACE induces a decrease in systemic vas-
cular resistance, an increase in renal plasma ﬂow and
stimulates salt excretion, making ACE inhibitors
potent antihypertensive therapies. Furthermore,
ACE inhibitors have demonstrated in adulthood to
have a renoprotective potency in adulthood by ﬁrst
inducing vasodilatation of the efferent arteriole and
decreasing the ﬁltration pressure, and thus the
degree of proteinuria. Second, they suppress local
growth and inﬂammatory factors, subsequently
leading to a reduction of glomerular hypertrophy,
sclerosis, tubulointerstitial inﬂammation and ﬁbro-
sis.4 Since hypertension in childhood is most fre-
quently secondary to a renal parenchymal disease,
ACE inhibitors are recognised as very useful antihy-
pertensive therapies in the paediatric population.
Adverse effects that patients treated with ACE inhibi-
tors can encounter are hypotension, cough, hyperka-
laemia, acute kidney injury, fetal anomalies and
angioedema. Neutropenia, rash and nephrotic-range
proteinuria are adverse events (AEs) especially
related to the sulfhydryl group of captopril.4 In
patients with volume depletion, bilateral renal artery
stenosis or unilateral renal artery stenosis in a single
kidney, an ACE inhibitor can induce an important
drop in glomerular ﬁltration rate (GFR).4
ACE inhibitors are one of the prototype drugs
targeted by strong incentives introduced worldwide
to improve access to safe and effective medicines
addressing the therapeutic needs of children.5 In
1997, the USA launched the pioneering legislation
that aimed to promote drug licensing and labelling
for children: the ‘Food and Drug Administration
(FDA) Modernization Act’, followed by the ‘Best
Pharmaceuticals for Children Act’ in 2002, the
‘Research Equity Act’ in 2003 and the FDA
Amendments Act and the FDA Safety and
Innovation Act in 2012. In 2007, the European
Union’s Paediatric Regulation and the World Health
Assembly of Resolution WHA60.20 followed, based
on the US experience. These incentives resulted in
an increased number of published clinical trials in
hypertensive children. In 2014, the ﬁrst comprehen-
sive Cochrane review about pharmacological inter-
ventions in hypertensive children was published
evaluating randomised controlled trials (RCTs) with
antihypertensive therapies, including ACE inhibi-
tors.6 However, only four trials evaluating enalapril,
lisinopril and fosinopril were included and the
review was not believed to be robust enough to
provide ﬁrm recommendations for ﬁrst-line agents
in children with hypertension.6
As a consequence in clinical practice, the selec-
tion of the most appropriate ACE inhibitor therapy
in children remains a challenge and many clinical
questions continue to exist. Our purpose in
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assembling this review was to evaluate and describe all the
current evidence for the efﬁcacy and safety proﬁle of ACE inhi-
bitors in the paediatric hypertensive population and with it to
formulate the remaining questions.
MATERIALS AND METHODS
A literature search was performed in PubMed, including
abstracts from 1980 to April 2015. Search terms included hyper-
tension, child, paediatric, ACE (inhibitors), RAS and kallikrein-
kinin system, and following drugs: captopril, lisinopril, enala-
pril, ramipril and fosinopril. We then continued with the ‘snow-
ball method’ by looking for references in recent publications
and reviews. All intervention studies and observational studies
on efﬁcacy and safety of ACE inhibitors in hypertensive children
(0–18 years) were included in this review. Trials not published in
English, editorial pieces and opinions were excluded. The
studies were analysed and the following information was col-
lected: design, number of patients, age, ACE inhibitor, dose, for-
mulation, intervention, primary and secondary end points,
antihypertensive events and AEs. To assess the risk of bias of the
included studies, we used the Newcastle-Ottawa Scale (NOS)
for cohort studies, evaluating the selection of the study groups,
the comparability of the groups and the ascertainment of the
outcome of interest.7 The Cochrane Collaboration’s tool for
assessing risk of bias was used to evaluate randomised studies by
scoring sequence generation, allocation concealment, blinding,
incomplete or selective outcome reporting and others.8
RESULTS
A total of 16 studies evaluating efﬁcacy and safety of ACE inhi-
bitors in the paediatric hypertensive population were included
in this review (see table 1).9–26 To explore the differences
between ACE inhibitors, the studies were grouped according to
the evaluated ACE inhibitor: captopril (7), lisinopril (3), enala-
pril (2), fosinopril (1) and ramipril (3).9–26 Most of the studies
were cohort studies with retrospective or prospective data
collection. So far four double-blind RCTs have been pub-
lished.15 17–20 Three of them (lisinopril, enalapril and fosino-
pril) were developed according to a type C design, including
initial randomisation, followed by two or more active treatment
arms (eg, low, medium and high dosage), a second randomisa-
tion to double-blind withdrawal to placebo, and an open-label
‘safety’ phase.15 17 19 20 The ESCAPE trial, evaluating the time
to 50% decrease in GFR or progress to end-stage renal disease
(ESRD) in intensiﬁed versus conventional blood pressure (BP)
control with ramipril treatment, used a prospective open-label
RCT design.24 The quality of the included RCT was very vari-
able. Using the Cochrane Collaboration’s tool, the risk of bias
was low for sequence generation, blinding and incomplete
outcome data in only 2/5 trials. Information about allocation
concealment was only available for one study. Assessment of
selective outcome reporting was considered low in all included
RCTs. Three of the included studies were supported by the
industry.15 18–20 Except for the prospective cohort studies of
ramipril,22 25 the risk of bias (NOS≥6) in the cohort studies was
considered to be high.
Different deﬁnitions of hypertension were used in the studies.
Two of the studies deﬁned hypertension as a DBP of ≥95th per-
centile for age, gender and height on repeated measurements,
according to the ‘Fourth Report’.1 15 17 In contrast, an SBP of
≥95th percentile was used in two studies, and an SBP or a DBP
of ≥95th percentile was used in three studies.14 16 18–20 Soergel
et al,21 Seeman et al25 and Wühl et al22,24 deﬁned hypertension
as 24-hour mean systolic or diastolic arterial pressure ≥95th
percentile for age, gender and height. The proportion of chil-
dren with primary or secondary hypertension varied highly
between studies. Additionally, the fosinopril trial included chil-
dren with high-normal SBP or DBP, which were not included in
other trials.19 20 In contrast, captopril and ramipril were exclu-
sively evaluated in children with hypertension secondary to
renal disease.9–13 21 22 24 The GFR ranged from 11 to >90 mL/
min/1.73 m² and two studies included also children on dialy-
sis.11 26 Children with a GFR of <30 mL/min/1.73 m² were
excluded in ﬁve studies.15 17–20 26 Except for the study of
Mirkin et al12 and Callis et al,26 children with severe hyperten-
sion were always excluded from the studies.
The age range of the patients included varied from premature
infant to adolescents. Most of the studies were performed
in children ≥3 years. No RCT has been performed in children
<6 years.15 17–20 Captopril was the only ACE inhibitor evalu-
ated in neonates and premature infants (>25 weeks of gesta-
tional age).9 14 All included studies applied a weight-based dose
strategy for dose determination and a dose-ranging study design
was used in four trials.15 17–20 Only few reports documented
the formulation of the ACE inhibitor used in the study: suspen-
sion forms were evaluated for enalapril and tablets were used in
nine studies.9 12 15–20 22–24 The follow-up period of the partici-
pants varied widely from 3 days to 6.1 years.
Beside the ESCAPE trial, all studies used BP as their primary
outcome variable. In contrast, the ESCAPE trial used the time
to 50% decrease in GFR or progress to ESRD in intensiﬁed
versus conventional BP control with ramipril.24 The majority of
the studies used SBP with or without the combination of DBP as
their primary outcome variable.9–14 16–22 Only the lisinopril RCT
used DBP as their primary outcome variable.15 Most of the studies
determined BP auscultatory, 24 hours ambulatory blood pressure
measurement (ABPM) was used in four studies.18 21 22 24 25
Therapeutic efﬁcacy
Captopril
Captopril, the ﬁrst ACE inhibitor studied in the paediatric popu-
lation, has been evaluated in seven small studies including chil-
dren with hypertension due to renal disease.9–14 26 Mirkin
et al12 published the largest prospective study of 73 children
treated with captopril, and a signiﬁcant reduction in BP was
found, with a normalisation of the DBP and SBP after 6 months
in 45% and 53%, respectively. Similar BP reduction was found
in four other studies.10 11 13 26 Captopril was shown to be an
effective antihypertensive agent in neonates (n=20) of
>25 weeks of gestational age with a greater potency than in
older children.9 14
Lisinopril
Efﬁcacy of lisinopril has been evaluated in one RCT of 115
hypertensive children that found a clear dose-related response
of −0.28 mm Hg per unit increase in dose ratio in sitting DBP
in the middle-dose and high-dose group.15 Lisinopril adminis-
tration in hypertensive children has also been evaluated in a
retrospective study and was found to result in a decrease in both
SBP and DBP.16 The efﬁcacy of lisinopril has also been evaluated
in children with a renal transplant in a 30-day pharmacokinetic
study and was also found to decrease both SBP and DBP with
≥6 mm Hg in 85% and 77%, respectively.23
Enalapril
The efﬁcacy of enalapril has been studied in two large double-
blind RCTs, evaluating 110 and 281 hypertensive children,
respectively.17 18 Wells et al17 found a linear dose–response
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Table 1 An overview of all included studies evaluating captopril, lisinopril, enalapril, fosinopril and ramipril
Reference Drug Patients Dose, formulation Study design Outcome Effect
Quality of study (NOS; Cochrane
Collaboration’s tool)
Sinaiko et al11 Captopril n=10
Age: 3.5–20 years
Definition HT: ND
Population: secondary HT due to renal
parenchymal disease (4), renal
transplant rejection (4) or renal
artery stenosis (2)
Dose: 0.5–2.0 mg/kg, max.
6 mg/kg/day
Formulation: ND
Duration: 12 min
Design: prospective cohort,
no control population
Initially dose titration protocol,
followed by dose determination
according to magnitude and
duration effect in dose titration
Primary: ND
Secondary: ND
Reduction in mean SBP and DBP
≥10 mm Hg in all patients
after one, two or three doses
respectively 10–77 mm Hg,
2–67 mm Hg or 0–67 mm Hg
No correlation dose and magnitude of
BP reduction (p=0.37)
Selection
0/6
Comparability
0/2
Outcome
0/5
Mirkin et al12 Captopril n=73
Age: 11 days to 15 years
Definition: >95th percentile DBP and/or
SBP (according to Mitchell, Londe)
Population: refractory HT unresponsive
or intolerant to other
antihypertensive therapies, mainly
secondary, also with severe renal
impairment, dialysis
Dose: 0.3 mg/kg to max.
2 mg/kg 8q
Dose reduction in renal
impairment
Formulation: tablet or
crushed tablet dissolved
in water (<30 min
administered)
Duration: 3 min (n=30), 3–6 min
(n=10), 6–12 min (n=19),
>12 min (n=14)
Design: prospective cohort,
no control population
Primary: ND
Secondary: ND
Reduction in SBP and DBP (p<0.001)
Normalisation SBP and DBP after 6 min
in 53% and 45% of patients,
respectively
No decrease in efficacy over time
Discontinuation in 22 children because
of death (2), normalisation BP (1),
treatment failure (6), concurrent
illness (2), adverse event captopril
(2), others (5)
Selection
0/6
Comparability
0/2
Outcome
0/5
Sinaiko et al10 Captopril n=34
Age: premature infants to adolescents
Definition: ND
Population: 3 groups of children with
secondary HT: renal disease,
neonates, postTx
Dose: 0.01–2 mg/kg/day, in
neonates 0.01–0.5 mg/
kg/day
Formulation: ND
Duration: ND
Design: prospective cohort,
no control group
Primary: ND
Secondary: ND
Reduction in SBP and DBP in 94% in
post-Tx group
Increase in creatinine in 62% post renal
transplantation group (p<0.02)
Selection
0/6
Comparability
0/2
Outcome
0/5
Callis et al26 Captopril n=42
Age: 1–17 years (mean 11.2 years)
Definition: ND
Population: ESRD treated with
haemodialysis
Dose: 0.3–3 mg/kg/day
Formulation: ND
Duration: 1.5–6.1 years (mean
3.2 years)
Design: prospective cohort,
no control group
Primary: SBP, DBP
Secondary: renin,
aldosterone
Mean decrease of SBP from 162 to
114 mm Hg
Mean decrease of DBP from 106 to
86 mm Hg
After mean follow-up of 38 months all
obtained normal blood pressure
Selection
0/6
Comparability
0/2
Outcome
0/5
Bouissou et al13 Captopril n=25
Age: 1.5–18 years
Definition: >97.5 percentile of BP;
>10 mm Hg >97.5 percentile;
>30 mm Hg >97.5 percentile of BP
Population: severe HT due to renal
disease (10 on dialysis, 10 renal Tx)
Dose: initial 1.3 mg/kg/day,
sustained 2.2 mg/kg/day
Formulation: ND
Duration: 2–40 min, mean 15 min
Design: retrospective cohort,
no control group
Primary: SBP, DBP
Secondary: cardiomegaly,
tolerance
Compared with initial BP, an SBP and
DBP lowering of 26% at day 2 to
65% at 6 min was registered
Isolated use of captopril was ineffective
in 13% of cases
No relation between blood pressure
response and aetiology, degree HT
or plasma renin concentration
Normalisation of cardiomegaly in 3/5
patients
Selection
0/6
Comparability
0/2
Outcome
0/5
O’Dea et al9 Captopril n=11
Gestational age 27–43 weeks, age at
diagnosis HT 2–84 days; mean 23
±7.5 days
Definition: ND
Population: NICU, secondary HT
Dose: initial 0.13 (0.05) mg/
kg/day, sustained to
0.85 (0.13) mg/kg/day,
at day 21 0.48 (0.19)
mg/kg/day
Formulation: tablets in
water
Duration: 3–21 days
Design: prospective cohort,
no control group
Primary: ND
Secondary: ND
Positive antihypertensive response
(p<0.005): from 124(4)/84(4)
mm Hg pretreatment to 95(6)/59(4)
mm Hg post-treatment
Severe hypotension in one neonate
after initial dose of 0.5 mg/kg/day
Selection
0/6
Comparability
0/2
Outcome
0/5
Tack et al14 Captopril n=9
Gestational age 25–41 weeks, age at
diagnosis HT 10–72 days; mean 49
±28 days
Captopril started at 123±108 days
(range 10–269 days) postnatal age
Definition: > 95th percentile SBP
(>113 mm Hg)
NICU: chronic lung disease+HT
Dose: initial 0.3 mg/kg,
maintenance dose 0.2
±0.02 mg/kg
Formulation: ND
Duration 7–24 min
Design: retrospective cohort
Primary: SBP
Secondary: oliguria
Decrease SBP with 21–58% (mean 37
±15%)
Discontinuation in two patients due to
adverse event
Two patients died while receiving
captopril
17 episodes of decreased SBP ≥40%
from baseline
Selection
2/6
Comparability
0/2
Outcome
1/5
Continued
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Table 1 Continued
Reference Drug Patients Dose, formulation Study design Outcome Effect
Quality of study (NOS; Cochrane
Collaboration’s tool)
Soffer et al15 Lisinopril n=115
Age: 6–16 years
Definition: >95th percentile DBP
Population: mainly secondary HT,
GFR>30 mL/min/1.73 m²
Three different doses
(<50/>50 kg):
Low: 0.02 mg/kg (0.625/
1.25 mg)
Middle: 0.07 mg/kg
(2.5/5 mg)
High: 0.61 mg/kg
(20/40 mg)
Formulation: tablets
Duration: dose ranging (2 weeks)
+randomised washout
(2 weeks)
Design: prospective, double-blind
randomised, placebo-controlled,
industry driven
Primary: DBP
Secondary: SBP
Increasing doses resulted in greater
reductions in sitting DBP (low,
−7.6 mm Hg; medium,
−9.3 mm Hg; high, −16.4 mm Hg)
↓0.28 mm Hg in sitting DBP/unit ↑ in
dose ratio (p<0.01), similar findings
for sitting SBP
Mean difference in DBP between
lisinopril and placebo 6.19
±1.86 mm Hg−low dose=placebo
Sequence
generation
unclear
Incomplete
outcome
unclear
Allocation
concealment
unclear
Selective
outcome
low
Blinding
unclear
Others
high
Raes et al16 Lisinopril n=59
Age: 0.2–17.6 years
Definition: >95th percentile DBP or SBP
Population: primary HT (1), renal
disease (58)
Dose: mean 0.105 mg/kg,
range 0.1–0.5 mg/kg
Formulation: tablets,
capsules with crushed
tablets in young children
Duration: 2±1.8 years
Design: retrospective
Primary: BP
Secondary: height
↓ SBP of 19 mm Hg
↓ DBP of 18 mm Hg
Growth unaffected
Other antihypertensive necessary in 12
of 59
Selection
1/6
Comparability
0/2
Outcome
1/5
Trachtman et al23 Lisinopril n=13
Age: 7–17 years
Definition: ≥75th percentile SBP
Population: stable kidney Tx,
GFR≥30 mL/min/1.73 m²
Stable allograft function and
immunosuppressive regimen
Exclusion: other ACEI or ARB, allergy,
stage 2 HT, serum potassium
>6 mmol/L
Dose: 0.1–0.4 mg/kg
Formulation: tablets
Duration: BP during PK, safety until
30 days after PK
Design: prospective, open-label
cohort study
Primary: pharmacokinetic
properties
Secondary: BP, safety
Decrease in SBP of 9.0±6.9 and 85%
had ≥6 mm Hg decrease in SBP
Decrease in DBP of 6.2±9.9 and 77%
had ≥6 mm Hg decrease in DBP
Selection
0/6
Comparability
0/2
Outcome
2/5
Wells et al17 Enalapril n=110 (>20 kg)
Age: 6–16 years
Definition: >95th percentile DBP
Population: >50% renal disease,
GFR>30 mL/min/1.73 m²
Exclusion: severe/symptomatic
HT; comorbid situations
Three different doses
(<50/>50 kg):
Low: 0.02 mg/kg (0.625/
1.25 mg)
Middle: 0.08 mg/kg
(2.5/5 mg)
High: 0.58 mg/kg
(20/40 mg)
Formulation: suspension in
low-dose group, tablets
Duration: dose ranging (2 weeks)
+randomised washout
(2 weeks)
Design: prospective, double-blind
randomised, placebo-controlled
Primary: DBP
Secondary: SBP
Decrease of DBP of 6.3, 8.9, and
14.9 mm Hg for the low group,
middle group and high-dose group
Decrease of SBP of were 7.1, 6.6 and
12.5 mm Hg in the low group,
middle group and high-dose group
↓0.3 mm Hg in sitting DBP/unit ↑in
dose ratio (p<0.001)
Linear dose–response ratio
Mean difference DBP
enalapril↔placebo 6.1±2.0 mm Hg
Low dose=placebo
Sequence
generation
unclear
Incomplete
outcome
unclear
Allocation
concealment
unclear
Selective
outcome
low
Blinding
unclear
Others
unclear
Schaefer et al18 Enalapril
or
valsartan
n=281
Age: 6–17 years
Definition: > 95th percentile SBP
Population: 32% renal/urological
disease, 17% CKD,
GFR>30 mL/min/1.73 m²
Dose enalapril/valsartan
18–35 kg: 10 mg/80 mg
35–80 kg: 20 mg/160
mg
80 kg: 40 mg/320 mg
Formulation: tablets
Duration: 1 week half of assigned
dose, 11 week full dose
Design: prospective, double-blind
randomised, parallel group,
active-controlled, industry
driven
Primary: SBP
Secondary: DBP, %
achieving control
↓ mean SBP/DBP enalapril and
valsartan −13.0/−8.2, −11.8/−7.9
(p<0.0001)
↓ mean SBP similar for enalapril and
valsartan (p<0.0001)
Similar SBP control enalapril (70%),
valsartan (67%) (p=0.49)
24 hours ABPM: valsartan greater MAP
↓ than enalapril (p=0.03)
Sequence
generation
unclear
Incomplete
outcome
low
Allocation
concealment
unclear
Selective
outcome
low
Blinding
unclear
Others
high
Li et al19+extrapolation by
Menon et al20
Fosinopril n=253
Age: 6–16 years
Definition HT: > 95th percentile DBP or
SBP; high normal BP: 90–95
percentile of DBP or SBP
Three different doses
fosinopril:
Low: 0.1 mg/kg, > 60 kg
10 mg
Middle: 0.3 mg/kg,
> 60 kg 20 mg
Duration: dose ranging (2 weeks),
randomised washout (2 weeks),
open-label safety study
(52 weeks)
Design: prospective, double-blind
randomised, placebo-controlled
Primary: SBP
Secondary: DBP, %<90th
percentile DBP and
SBP, safety, racial
difference
Three doses equally effective in
lowering SBP (low −10.9 mm Hg,
medium −11.3 mm Hg, high
−11.9 mm Hg), no dose-response
(p=0.53)
Sequence
generation
low
Incomplete
outcome
low
Allocation
concealment
low
Selective
outcome
low
Blinding
low
Others
high
Continued
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Table 1 Continued
Reference Drug Patients Dose, formulation Study design Outcome Effect
Quality of study (NOS; Cochrane
Collaboration’s tool)
Population: HT, high normal BP
+associated condition (diabetes
mellitus, renal disease in 20.9%)
High: 0.6 mg/kg, >60 kg
40 mg (max 40 mg)
Formulation: tablet
Industry driven Withdrawal effect to placebo of
3.7 mm Hg
40–60% reached BP control
−13/−8.3 mmHg decrease in BP at
week 52
No dose–response in non-black patients
Blacks: significant dose–response
(p=0.03)
Soergel et al21 Ramipril n=14
Age: 5–18 years
Definition: 24-hour mean systolic or
diastolic ABPM >95th percentile
Population: secondary HT, renal disease
(CKD, 4/14 GFR<60 mL/min/
1.73 m²)
Exclusion: renal Tx, non-compliance
Dose: ramipril 1.5–3 mg/m²
monotherapy
Formulation: ND
Duration: 6 months
Design: prospective cohort study,
no control population
Primary: mean SBP and
DBP
Secondary: nocturnal
dipping
Decrease in mean SBP and DBP of 9
and 8 mm Hg, respectively
Maximal decrease of mean SBP and
DBP was 17 and 14 mm Hg,
respectively
Mean SBP nocturnal dipping: before:
6.9%±4.8%, 2 weeks: 8.7%±3.7%
(p=0.12), 6 months: 10.9%±4.6%
(p=0.03)
Mean DBP nocturnal dipping: before:
12.3%±5.2%, 2 weeks: 18.2%
±3.3% (p=0.01), 6 months: 17.1%
±8.2% (p=0.07)
Selection
2/6
Comparability
0/2
Outcome
2/5
Seeman et al25 Ramipril n=31
Age: 1.9–19.8 y (mean 11.3 years)
Definition: mean SBP and/or DBP ABPM
≥95th percentile
Population: chronic kidney disease with
HT or proteinuria, GFR>30 mL/min/
1.73 m2
Dose: ramipril 1.5–6 mg/m2/
day
Formulation: ND
Duration: 6 months
Design: prospective cohort, no
control population
Primary: BP
Secondary: proteinuria
Mean decrease in ABPM of 11 mm Hg
for daytime SBP, 10 mm Hg for
daytime and night-time DBP and
8 mm Hg night-time SBP
Normalisation of BP in 55% of children
Proteinuria decreased in 84% of
children
Selection
3/6
Comparability
0/2
Outcome
3/5
Wühl et al+continuation
by Wühl et al22 24
(ESCAPE trial)
Ramipril n=352 (interim), n=385 (final)
Age: 3–18 years
Definition: 24-hour mean systolic or
diastolic ABPM >95th percentile
Population: secondary HT due to CKD
(GFR ranges from 11–80 mL/min/
1.73 m²)
Exclusion: renal artery stenosis, renal
Tx, unstable condition
Dose: ramipril 6 mg/m²
Formulation: tablets
Duration: 6 months (interim),
extension to 5 years (final)
Design: prospective cohort study,
multicentric study in interim
study, randomised, open-label
study for final analysis
Interim 6 months: BP,
urinary protein
Final study: primary: time
to a decline of 50% in
GFR or progression to
ESRD
Secondary: BP, GFR and
urinary protein
excretion
↓ MAP of 11.6 mm Hg, BP control in
65% after 6 months
MAP decreased from 89.3 mm Hg at
baseline to 81.9 mm Hg at month 6
Effect equally for day/night and systolic/
diastolic
Linear correlation initial MAP and
change in MAP during therapy
(r=0.51, p<0.0001)
Greater ↓ mean 24-hour MAP when
GFR<40 mL/min/1.73 m² (p<0.005)
35% ↓ in relative risk of losing 50% in
GFR or progression to ESRD in
intensified BP control group
29.9% vs 41.7% of reaches primary
end point in intensified and
conventional group, respectively
Interim
(6 months)
Selection
2/6
Final (5 years)
Sequence
generation
low
Incomplete
outcome
low
Comparability
½
Allocation
concealment
unclear
Selective
outcome
low
Outcome
3/5
Blinding
low
Others
high
To assess the risk of bias of the included studies, the NOS was used for cohort studies, evaluating selection of the study groups, the comparability of groups and ascertainment of the outcome of interest.7 The Cochrane Collaboration’s tool for assessing
risk of bias was used to evaluate for randomised studies, scoring sequence generation, allocation concealment, blinding, incomplete or selective outcome reporting and others.8.
ABPM, ambulatory blood pressure measurement; ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CKD, chronic kidney disease; DBP, diastolic blood pressure; ESRD, end-stage renal disease; GFR, glomerular filtration rate; HT,
hypertension; MAP, mean arterial blood pressure; max, maximum; NICU, neonatal intensive care; n, number; ND, not defined; NOS, Newcastle-Ottawa Scale; PK, pharmacokinetics; SBP, systolic blood pressure; Tx, transplantation.
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ratio, more speciﬁcally a decrease of 0.3 mm Hg in DBP per
unit increase in dose ratio, and a signiﬁcant mean difference in
DBP of 6.1±2 mm Hg between the three groups of enalapril
compared with placebo. Schaefer et al18 compared valsartan
with enalapril in an active-controlled RCT and found that both
drugs were equally effective in reducing BP compared with base-
line. In the subgroup of children that had a 24-hour ABPM,
valsartan was found to provide a signiﬁcant greater mean
arterial SBP reduction than enalapril.18
Fosinopril
Fosinopril has been studied in one placebo-controlled RCTwith
253 children with hypertension or a high normal BP.19 20 The
three evaluated doses of fosinopril were found to be equally
effective in lowering SBP.19 20 However, a signiﬁcant dose–
response was found in black children, which was absent in non-
black children, indicating that black children may need higher
doses per body weight.20 In this study population, 40–60%
of the children reached BP control and a decrease of
−13/−8.3 mm Hg in BP was reached at 52 weeks follow-up.
Ramipril
Soergel et al21 and Seeman et al25 prospectively followed 14
and 31 children respectively taking ramipril and found a signiﬁ-
cant decrease in both SBP and DBP and nocturnal dipping. In
the interim analysis of the ESCAPE trial, evaluating 352 chil-
dren with chronic kidney disease after 6 months treatment with
ramipril, a signiﬁcant decrease in mean SBP of 11.6 mm Hg and
a greater decrease in SBP was shown in children with a GFR of
<40 mL/min/1.73 m².22 In the ﬁnal analysis of the ESCAPE
trial, 385 children were randomised to intensiﬁed (<p50) or
conventional (p50–p90) BP control to compare the time until
they lose ≥50% in GFR or they progress to ESRD.24 This
primary end point was reached in respectively 41.7% versus
29.9% of the children. Intensiﬁed BP control was found to have
a 35% lower risk to lose ≥50% in GFR or progress to ESRD.24
Safety proﬁle of ACE inhibitors
The short-term safety proﬁle of lisinopril, enalapril and fosino-
pril in children 6–16 years was evaluated in detail; however,
long-term safety data are lacking. Ramipril and captopril are the
only ACE inhibitors in which the safety proﬁle has been evalu-
ated over a period of ≥5 years. All the AEs, included in the
studies evaluating ACE inhibitors, are summarised in table 2.
Since the study design (retrospective vs prospective), the dur-
ation of follow-up and the characteristics of the study popula-
tions (age, comorbidities, renal function) were very different,
comparison between the different ACE inhibitors is difﬁcult.
Dizziness, vertigo, postural symptoms and headache were fre-
quently reported as AEs, especially in the enalapril and fosino-
pril trials.17–20 The incidence of hypotension in the captopril
studies was remarkably high in contrast to the other ACE inhibi-
tors.9–14 The incidence of increased creatinine and/or blood
urea nitrogen (BUN) varied among the different trials from
absent to 62% in the study of Sinaiko et al.10 The ESCAPE
trial, including only children with chronic kidney disease (GFR
11–80 mL/min/1.73 m²), reported an increase in creatinine in
50 of the 385 participants of the study population.24 The inci-
dence of cough in the studies was widely different between the
studies but was remarkably lower than in the adult studies, which
report cough in almost 20% of the participants.27 Angioedema
has not been reported in these studies.
Only a few serious AEs were reported in the included studies:
acute kidney injury in one child with an underlying renal arteria
stenosis receiving captopril and one child receiving enalapril,
severe hypotension with oliguria in one neonate receiving capto-
pril, haemorrhagic infarction in one neonate receiving captopril
and avulsion fracture in one child receiving enalapril.9 13 18 No
related deaths were reported after receiving ACE inhibitors.
DISCUSSION
Thanks to the initiatives of the USA, Europe and the WHO, an
overall increase in clinical trials evaluating the efﬁcacy and
safety of ACE inhibitors occurred. Overall, ACE inhibitors have
demonstrated to have the potency to decrease the SBP and/or
DBP with an overall favourable safety proﬁle in a short-term
period. More importantly, paediatric labelling by the FDA
Reports was obtained for three of the ﬁve discussed ACE in-
hibitors in the paediatric hypertensive population: lisinopril
(for children ≥6 years), enalapril (for children ≥1 month) and
fosinopril (for children ≥6 years).28
However, is it really true that the promising legislative initia-
tives and the improved paediatric labelling narrowed the gap
between the availability of ACE inhibitors labelled and indicated
for paediatric use and the actual drug usage in children? Welch
et al29 reported that still 25.5–33.1% of the children are receiv-
ing unlabelled or not indicated antihypertensive medications.
Furthermore, they report that still 7% of all the prescribed anti-
hypertensive drugs were prescribed ‘off-label’ in children, with
neither FDA-approved paediatric label information nor dosing
recommendations in the Fourth Report. The risks of ‘off-label’
use are generally accepted and recently highlighted by Wharton
et al,30 which demonstrated that a quarter of the drugs that
received new paediatric labelling obtained a new paediatric
safety signal. Furthermore, the recently published Cochrane
review evaluating the efﬁcacy and safety of antihypertensive
therapies, including ACE inhibitors, could only include four
studies evaluating lisinopril (1), enalapril (2) and fosinopril (1)
in the analysis.6 15 17–20 Since trials comparing an ACE inhibitor
directly to placebo are lacking, ACE inhibitors were not
included in the meta-analysis. Consequently, the Cochrane
review failed to provide ﬁrm recommendations for ACE inhibi-
tors in the paediatric hypertensive population.6 Therefore, we
assumed to summarise all the current evidence available on ACE
inhibitors in the paediatric population in this review, including
also non-randomised studies. Although we recognise that the
majority of these non-randomised studies were of low quality
with high risk of bias, they are currently the only studies report-
ing about the use of ACE inhibitors in high-risk populations
(neonates, young children, children with renal transplant,
chronic kidney disease, ESRD, etc) in contrast to the highly
selected mild hypertensive population in RCT.
Although the efﬁcacy and safety proﬁle and labelling status of
ACE inhibitors improved over time, they still do not meet with
the true clinical relevance and several obstacles have to be con-
quered. First, we have to realise that the efﬁcacy of ACE inhibi-
tors is only evaluated based on BP, a surrogate outcome variable
and the proof of efﬁcacy of ACE inhibitors on hard outcome
variables such as end-organ damage, cardiovascular morbidity
or mortality in adulthood is completely lacking. Also, the use of
24-hour ABPM in clinical trials was poor. Furthermore, the
studies evaluated ACE inhibitors only in a short period and the
long-term effect and safety of ACE inhibitors on growth, puber-
tal development and maturation is still unknown.
A second important limitation of these studies is the incom-
plete inclusion of the population of children with hypertension.
Besides the studies of ramipril, captopril and Trachtman et al,
most of the studies concentrated on mild hypertensive patients
6 Snauwaert E, et al. Arch Dis Child 2016;0:1–9. doi:10.1136/archdischild-2016-310582
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Table 2 Summary of all adverse events reported in the included studies
N Drug Hyperkalaemia Increased creatinine and/or BUN Cough
Dizziness, vertigo, headache,
postural symptoms,
hypotension Gastrointestinal Others
Sinaiko et al11 10 Captopril / / / / / Neutropenia (2)
Mirkin et al12 73 Captopril Potassium
significantly elevated,
but <5 mmol/L
BUN significantly increased from 22.9–
29.8 mg/dL to 31.5–39.1 mg/dL
(p<0.001)
Creatinine increased from 1.11 mg/dL to
1.3 mg/dL (p<0.05)
19/50 had increase of creatinine >50%,
5/19 did had bilateral renal artery
stenosis (of unilateral in single
kidney)
/ Hypotension (7), postural
symptoms (5)
Vomiting (5),
anorexia (3)
Leucopenia (6), anaemia (4), rash (4)
Sinaiko et al10 34 Captopril / In 62% of study population increase in
creatinine
Mean increase in serum creatinine from
1.1 (0.1) to 1.7 (0.2) mg/dL in renal
transplant group (p<0.05)
/ Hypotension (1) in patient with
renal artery stenosis and heart
failure
/ /
Callis et al26 42 Captopril Mean 5.3±0.7 mmol/
L
/ / / / Pruritus and rash (1), ageusia (12),
leucopenia (2)
Bouissou et al13 25 Captopril Mean increase of
1.6 mmol/L,
non-severe
hyperkalaemia
/ / Transient vomiting (1) /
O’Dea et al9 11 Captopril / / / Hypotension with oliguria (1),
dose 0.5 mg/kg/day
/ Acute kidney injury in child with renal
artery stenosis in transplant kidney
Tack et al14 9 Captopril / / / Hypotension with >40%
reduction in blood pressure from
baseline (9), oliguria (4)
/ Neurological symptoms during
hypotension: subtle seizure activity (2),
haemorrhagic infarction (1) and ashen
colour, apnoea and rhythmic arm
movements suggestive of seizures (1)
Soffer et al15 115 Lisinopril Hyperkalaemia (1) Increased creatinine and BUN (2) Cough (1),
not related
lisinopril
Headache (4), dizziness (2) Abdominal pain,
diarrhoea, nausea
and vomiting (2)
Leucopenia (1)
Raes et al16 59 Lisinopril / / Cough (1) Hypotension (7), headache (1),
vertigo (2)
/ Death (5) (non-lisinopril related),
anaemia (1), headache, tachycardia,
dizziness, hypovolaemia and dyspnoea
(1), tachycardia (1)
Trachtman et al23 13 Lisinopril / GFR decrease >20% (1) / Dizziness (2) Nausea (2), stomach
ache
Gastroenteritis with hospitalisation (1)
Wells et al17 110 Enalapril No difference in
pre- potassium and
post-potassium
Slight increase BUN and/or creatinine (5)
No difference in pre-BUN and post-BUN,
creatinine
Cough (3 of
which 1
lisinopril
related)
Dizziness (4), headaches (2) / Chest pain, increased blood pressure,
hypotension, diarrhoea, cough,
dyspnoea, pruritus, rash, and blurred
vision (1)
Schaefer et al18 281 Enalapril,
valsartan
Potassium
>5.5 mmol/L (4),
potassium >6 mmol/L
(4)
/ / / / Avulsion fracture (1), renal injury (1)
253 Fosinopril Hyperkalaemia (1) / Headache (20.1%)
Continued
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and children with comorbidities such as severe renal impairment,
renal transplantation or severe hypertension were excluded.
However, children with comorbidities are known to present with
more severe and therapy-resistant hypertension, which require
higher doses of ACE inhibitors or combination therapy to control
the BP. Furthermore, the risk of AEs (eg, hyperkalaemia) is
extremely higher in children with renal impairment, renal trans-
plantation or in children taking concomitant transplant medica-
tion (eg, tacrolimus, ciclosporin).
In addition to the previous remarks, the poor availability of
labelled ACE inhibitors, indicated for the younger children
(<6 years) and neonates, has to be highlighted. Among the dis-
cussed ACE inhibitors, enalapril is the only ACE inhibitor with
paediatric labelling for children younger than 6 years.28 To date,
no ACE inhibitor has been evaluated by a proper conducted
RCT in children younger than 6 years or neonates. For this age
group, only studies with small study samples and/or poor design
(retrospective, no control group) are available for captopril,
lisinopril and ramipril (>3 years). The fact that there are no
efﬁcacy and/or safety studies for young children and neonates is
unfortunate as most of them will have secondary forms of
hypertension that may require multiple medications to achieve
adequate BP control. In contrast to the other studies, the preva-
lence of hypotension as AE was remarkably high in the captopril
studies evaluating neonates and preterm born infants. This is
not surprising since neonates have a lower GFR (and thus a
longer serum half-life) and the neonatal kidney is dependent on
the angiotensin II postglomerular efferent arteriole vasoconstric-
tion to maintain BP.9 14 31 Additionally, the deleterious effects
of ACE inhibitors during the second and/or third trimester of
pregnancy are well described: renal tubular dysgenesis, fetal
anuria leading to oligohydramnios and the Potter sequence of
facial dysmorphy, limb-positioning defect and lung hypoplasia
associated with skull ossiﬁcation defect.32 The question if ACE
inhibition should be avoided in the immature kidney remains
unanswered.
At last, the incentives did not result in an improved availabil-
ity of age-appropriate formulations. Until nowadays, no suspen-
sion for ACE inhibitors is commercially available, limiting
consequently a safe and child-friendly administration of these
medications in the paediatric population.
Therefore, a greater effort to improve paediatric labelling is
necessary, with special attention for children <6 years, neonates
and children with severe renal impairment, severe hypertension
or renal transplant.
CONCLUSION
The recent legislative initiatives increased the availability of
paediatric labelling of ACE inhibitors. Nevertheless, many drugs
used by hypertensive children have an insufﬁciently mapped
out efﬁcacy and safety proﬁle and lack paediatric labelling.
Moreover, many clinical questions remain and consequently
complicate the selection of the most appropriate and effective
ACE inhibitor in hypertensive children. The legislative initiatives
also failed to fulﬁl several of paediatric needs: absence of long-
term safety data on growth and maturation, absence of commer-
cially available child-friendly formulations and incomplete
evaluation of the entire paediatric hypertension population.
Additional efforts are needed to close the gap between the avail-
ability of drugs that are labelled and indicated for paediatric use
and the actual drug usage in children, especially in young chil-
dren, neonates and children with severe hypertension, renal
transplantation or severe renal impairment.
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